Median overall survival was @ months ( @ % CI @-not reached ) in the dabrafenib and trametinib group versus @ months ( @-@ ) in the dabrafenib only group ( hazard ratio -LSB- HR -RSB- @ , @ % CI @-@ ; p = @ ) .